ArticleOncotarget2016
Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Molecular pathology of phyllodes tumours of the breast-much more than MED12.Histopathology · 2026Review
- A Comparative Study on Copy Number Variation in Subtypes of Breast Phyllodes Tumors.Breast cancer : basic and clinical research · 2025Article
- CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor.Breast cancer research and treatment · 2025Article
- Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.JCO precision oncology · 2024Article
- IntragenicCancers · 2023Article
- Co expression of EGFR and CD10 in patients with phyllodes tumors of the breast: a single center experience in North Western Algeria.African health sciences · 2023Article
- An integrative approach for exploring the nature of fibroepithelial neoplasms.British journal of cancer · 2023Article
- Fibroepithelial tumours of the breast-a review.Virchows Archiv : an international journal of pathology · 2022Review
- Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers.Orphanet journal of rare diseases · 2021Article
- Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.British journal of cancer · 2018Article
- Article
- Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.Molecular oncology · 2017Article
- Palliative treatment of metastatic phyllodes tumors: a case series.AME case reports · 2017Article
- Atypical Distant Metastasis of Breast Malignant Phyllodes Tumors: A Case Report and Literature Review.Case reports in obstetrics and gynecology · 2017Article
- Bone metastasis from malignant phyllodes breast tumor: report of two cases.BMC clinical pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant phyllodes tumor is a rare breast malignancy with sarcomatous overgrowth and with limited effective treatment options for recurrent and metastatic cases. Recent clinical trials indicated a potential for anti-angiogenic, anti-EGFR and immunotherapeutic approaches for patients with sarcomas, which led us to investigate these and other targetable pathways in malignant phyllodes tumor of the breast. Thirty-six malignant phyllodes tumors (including 8 metastatic tumors with two cases having matched primary and metastatic tumors) were profiled using gene sequencing, gene copy number analysis, whole genome expression, and protein expression. Whole genome expression analysis demonstrated consistent over-expression of genes involved in angiogenesis including VEGFA, Angiopoietin-2, VCAM1, PDGFRA, and PTTG1. EGFR protein overexpression was observed in 26/27 (96%) of cases with amplification of the EGFR gene in 8/24 (33%) cases. Two EGFR mutations were identified including EGFRvIII and a presumed pathogenic V774M mutation, respectively. The most common pathogenic mutations included TP53 (50%) and PIK3CA (15%). Cases with matched primary and metastatic tumors harbored identical mutations in both sites (PIK3CA/KRAS and RB1 gene mutations, respectively). Tumor expression of PD-L1 immunoregulatory protein was observed in 3/22 (14%) of cases. Overexpression of molecular biomarkers of increased angiogenesis, EGFR and immune checkpoints provides novel targeted therapy options in malignant phyllodes tumors of the breast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.